HomeCompareMBXBF vs PLD

MBXBF vs PLD: Dividend Comparison 2026

MBXBF yields 1162.79% · PLD yields 3.18%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MBXBF wins by $71037541.84M in total portfolio value
10 years
MBXBF
MBXBF
● Live price
1162.79%
Share price
$0.17
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$71037548.35M
Annual income
$60,758,695,090,499.19
Full MBXBF calculator →
PLD
PLD
● Live price
3.18%
Share price
$128.78
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.50M
Annual income
$5,256,436.18
Full PLD calculator →

Portfolio growth — MBXBF vs PLD

📍 MBXBF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMBXBFPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MBXBF + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MBXBF pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MBXBF
Annual income on $10K today (after 15% tax)
$98,837.21/yr
After 10yr DRIP, annual income (after tax)
$51,644,890,826,924.31/yr
PLD
Annual income on $10K today (after 15% tax)
$270.62/yr
After 10yr DRIP, annual income (after tax)
$4,467,970.75/yr
At 15% tax rate, MBXBF beats the other by $51,644,886,358,953.56/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MBXBF + PLD for your $10,000?

MBXBF: 50%PLD: 50%
100% PLD50/50100% MBXBF
Portfolio after 10yr
$35518777.43M
Annual income
$30,379,350,173,467.69/yr
Blended yield
85.53%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

MBXBF
No analyst data
Altman Z
1.4
Piotroski
2/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+5.6% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MBXBF buys
0
PLD buys
0
No recent congressional trades found for MBXBF or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMBXBFPLD
Forward yield1162.79%3.18%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$71037548.35M$6.50M
Annual income after 10y$60,758,695,090,499.19$5,256,436.18
Total dividends collected$70267668.95M$6.37M
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: MBXBF vs PLD ($10,000, DRIP)

YearMBXBF PortfolioMBXBF Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$126,979$116,279.07$11,255$555.24+$115.7KMBXBF
2$1,515,775$1,379,907.30$13,062$1,018.59+$1.50MMBXBF
3$17,016,490$15,394,610.53$15,903$1,926.67+$17.00MMBXBF
4$179,725,369$161,517,725.51$20,839$3,823.32+$179.70MMBXBF
5$1,786,627,353$1,594,321,207.48$30,464$8,166.08+$1786.60MMBXBF
6$16,723,791,389$14,812,100,121.30$52,054$19,457.30+$16723.74MMBXBF
7$147,473,158,468$129,578,701,682.00$109,886$54,188.93+$147473.05MMBXBF
8$1,225,690,132,710$1,067,893,853,149.49$304,030$186,451.18+$1225689.83MMBXBF
9$9,606,404,914,243$8,294,916,472,243.00$1,166,125$840,813.32+$9606403.75MMBXBF
10$71,037,548,348,739$60,758,695,090,499.19$6,504,190$5,256,436.18+$71037541.84MMBXBF

MBXBF vs PLD: Complete Analysis 2026

MBXBFStock

Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. It manufactures a range of critical biological materials for the diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment and proficiency (QAPs) that support clinical lab proficiency testing, assay development and validation, or clinical lab workflows. The company also applies its biological expertise and infrastructure to develop other proprietary products, primarily viral transport medium (DxTM) to stabilize patient samples for lab-based testing and Kinlytic Urokinase, a biologic thrombolytic drug used to treat blood clots. It sells QAPs to lab accreditation organizations, diagnostics companies, and clinical labs through a network of regional distributors. Microbix Biosystems Inc. was founded in 1988 and is headquartered in Mississauga, Canada.

Full MBXBF Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this MBXBF vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MBXBF vs SCHDMBXBF vs JEPIMBXBF vs OMBXBF vs KOMBXBF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.